1od9: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 1od9 |SIZE=350|CAPTION= <scene name='initialview01'>1od9</scene>, resolution 2.10Å | |PDB= 1od9 |SIZE=350|CAPTION= <scene name='initialview01'>1od9</scene>, resolution 2.10Å | ||
|SITE= <scene name='pdbsite=BND:So4+Binding+Site+For+Chain+A'>BND</scene> | |SITE= <scene name='pdbsite=BND:So4+Binding+Site+For+Chain+A'>BND</scene> | ||
|LIGAND= | |LIGAND= <scene name='pdbligand=BND:ME-A-N-BENZOYL-AMINO-9-DEOXY-NEU5AC'>BND</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
|DOMAIN= | |||
|RELATEDENTRY= | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1od9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1od9 OCA], [http://www.ebi.ac.uk/pdbsum/1od9 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1od9 RCSB]</span> | |||
}} | }} | ||
| Line 29: | Line 32: | ||
[[Category: Maenaka, T.]] | [[Category: Maenaka, T.]] | ||
[[Category: Zaccai, N R.]] | [[Category: Zaccai, N R.]] | ||
[[Category: carbohydrate binding]] | [[Category: carbohydrate binding]] | ||
[[Category: immune system]] | [[Category: immune system]] | ||
| Line 37: | Line 38: | ||
[[Category: siglec]] | [[Category: siglec]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 22:43:37 2008'' | ||
Revision as of 22:43, 30 March 2008
| |||||||
| , resolution 2.10Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | |||||||
| Ligands: | , | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH ME-A-9-N-BENZOYL-AMINO-9-DEOXY-NEU5AC (BENZ COMPOUND)
OverviewOverview
The Siglec family of receptors mediates cell surface interactions through recognition of sialylated glycoconjugates. The crystal structure of the N-terminal immunoglobulin-like domain of the Siglec sialoadhesin (SnD1) in complex with 2,3-sialyllactose has informed the design of sialic acid analogs (sialosides) that bind Siglecs with significantly enhanced affinities and specificities. Binding assays against sialoadhesin (Sn; Siglec-1), CD22 (Siglec-2), and MAG (Siglec-4) show a 10- to 300-fold reduction in IC(50) values (relative to methyl-alpha-Neu5Ac) for three sialosides bearing aromatic group modifications of the glycerol side chain: Me-alpha-9-N-benzoyl-amino-9-deoxy-Neu5Ac (BENZ), Me-alpha-9-N-(naphthyl-2-carbonyl)-amino-9-deoxy-Neu5Ac (NAP), and Me-alpha-9-N-(biphenyl-4-carbonyl)-amino-9-deoxy-Neu5Ac (BIP). Crystal structures of these sialosides in complex with SnD1 suggest explanations for the differences in specificity and affinity, providing further ideas for compound design of physiological and potentially therapeutic relevance.
About this StructureAbout this Structure
1OD9 is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.
ReferenceReference
Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin., Zaccai NR, Maenaka K, Maenaka T, Crocker PR, Brossmer R, Kelm S, Jones EY, Structure. 2003 May;11(5):557-67. PMID:12737821
Page seeded by OCA on Sun Mar 30 22:43:37 2008